Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waiting to Exhale: Lilly Inhaled Insulin NDA Filing Will Wait For Safety Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III AIR safety study, which recently completed enrollment, will last 24 months.

You may also be interested in...



Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results

Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.

Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results

Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.

Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement

The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel